Home Title Index Topic Index Sources Directory News Releases Sources Calendar RSS Sources Select News RSS Feed

Clinical Trials
AlterLinks Topic Index

  1. ANAVEX 2-73 advances Phase I clinical trial for Alzheimer's disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs
  2. Anavex adds Dr. Paul Aisen to Scientific Advisory Board
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. (OTCBB: AVXL) has announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline
  3. Anavex advances second lead compound; initiates scale-up manufacturing of ANAVEX 1-41
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp., (“Anavex”) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a potential back-up compound to ANAVEX 2-73 in Alzheime
  4. Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
    Sources News Release

    Resource Type: Article
    Published: 2010
    Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
  5. Anavex appoints Dr. Jeffrey Cummings to its Scientific Advisory Board
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. has announced the appointment of Dr. Jeffrey Cummings to the Scientific Advisory Board as a clinical expert. The Scientific Advisory Board works closely with the company to support development of the Anavex product pipeline
  6. Anavex appoints Dr. Rachelle Doody to Scientific Advisory Board
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product
  7. Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer's Disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The
  8. Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer's Disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new
  9. Anavex strengthens management team with addition of VP, Clinical Development & Medical Affairs
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) announced the addition of Dr. Angelos Stergiou to the executive management team in the role of Vice President, Clinical Development & Medical Affairs. Dr. Stergiou has extensive medical and clinical
  10. Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York
    Sources News Release

    Resource Type: Article
    Published: 2010
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13
  11. Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer's Disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
  12. Brain Tumour Foundation of Canada
    Media Profile in Sources

    Resource Type: Organization
  13. Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert
    Media Profile in Sources

    Resource Type: Organization
  14. Private Profits vs Public Policy
    The Pharmaceutical Industry and the Canadian State

    Resource Type: Book
    Published: 2016
    According to Joel Lexchin, "Given the central role that medicines play in keeping us healthy, it is essential that we understand the policy environment that governs drug development, from the initial basic research to the sale of the manufactured produces to the patients that use them."

Experts on Clinical Trials in the Sources Directory

  1. World Health Organization

Sources-journalists use the sources website to find you


AlterLinks


© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.